279 related articles for article (PubMed ID: 29233126)
21. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
[TBL] [Abstract][Full Text] [Related]
23. EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas.
Petrini I; Lencioni M; Vasile E; Fornaro L; Belluomini L; Pasquini G; Ginocchi L; Caparello C; Musettini G; Vivaldi C; Caponi S; Ricci S; Proietti A; Fontanini G; Naccarato AG; Nardini V; Santi S; Falcone A
Cancer Biomark; 2018 Feb; 21(3):731-741. PubMed ID: 29278885
[TBL] [Abstract][Full Text] [Related]
24. Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China.
Shen GS; Zhao JD; Zhao JH; Ma XF; Du F; Kan J; Ji FX; Ma F; Zheng FC; Wang ZY; Xu BH
World J Gastroenterol; 2016 Jun; 22(23):5406-14. PubMed ID: 27340357
[TBL] [Abstract][Full Text] [Related]
25. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
27. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
[TBL] [Abstract][Full Text] [Related]
28. HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3.
Ruiz-Saenz A; Dreyer C; Campbell MR; Steri V; Gulizia N; Moasser MM
Cancer Res; 2018 Jul; 78(13):3645-3658. PubMed ID: 29760043
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients.
Yun S; Koh J; Nam SK; Park JO; Lee SM; Lee K; Lee KS; Ahn SH; Park DJ; Kim HH; Choe G; Kim WH; Lee HS
Gastric Cancer; 2018 Mar; 21(2):225-236. PubMed ID: 28573357
[TBL] [Abstract][Full Text] [Related]
30. LAPTM4B-35, a cancer-related gene, is associated with poor prognosis in TNM stages I-III gastric cancer patients.
Cheng X; Zheng Z; Bu Z; Wu X; Zhang L; Xing X; Wang X; Hu Y; Du H; Li L; Li S; Zhou R; Wen XZ; Ji JF
PLoS One; 2015; 10(4):e0121559. PubMed ID: 25849595
[TBL] [Abstract][Full Text] [Related]
31. The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways.
Jerjees DA; Negm OH; Alabdullah ML; Mirza S; Alkaabi M; Hameed MR; Abduljabbar R; Muftah A; Nolan CC; Green AR; Tighe PJ; Band V; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2015 Feb; 150(1):91-103. PubMed ID: 25701120
[TBL] [Abstract][Full Text] [Related]
32. HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells.
Amin DN; Sergina N; Lim L; Goga A; Moasser MM
Biochem J; 2012 Nov; 447(3):417-25. PubMed ID: 22853430
[TBL] [Abstract][Full Text] [Related]
33. ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer.
Moghbeli M; Makhdoumi Y; Soltani Delgosha M; Aarabi A; Dadkhah E; Memar B; Abdollahi A; Abbaszadegan MR
Biol Res; 2019 Jan; 52(1):2. PubMed ID: 30621788
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of HER3, PTEN and p-HER2 expression in patients with HER2positive breast cancer.
Dębska-Szmich S; Kusińska R; Czernek U; Szydłowska-Pazera K; Habib-Lisik M; Piekarski JH; Olas E; Kulig A; Ułańska M; Kalinka-Warzocha E; Potemski P
Postepy Hig Med Dosw (Online); 2015 May; 69():586-97. PubMed ID: 25983297
[TBL] [Abstract][Full Text] [Related]
35. JWA loss promotes cell migration and cytoskeletal rearrangement by affecting HER2 expression and identifies a high-risk subgroup of HER2-positive gastric carcinoma patients.
Qian J; Zhu W; Wang K; Ma L; Xu J; Xu T; Røe OD; Li A; Zhou J; Shu Y
Oncotarget; 2016 Jun; 7(24):36865-36884. PubMed ID: 27167206
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer.
Ema A; Yamashita K; Ushiku H; Kojo K; Minatani N; Kikuchi M; Mieno H; Moriya H; Hosoda K; Katada N; Kikuchi S; Watanabe M
Cancer Sci; 2014 Dec; 105(12):1591-600. PubMed ID: 25455899
[TBL] [Abstract][Full Text] [Related]
37. Prognostic implication of TSC1 and mTOR expression in gastric carcinoma.
Byeon SJ; Han N; Choi J; Kim MA; Kim WH
J Surg Oncol; 2014 Jun; 109(8):812-7. PubMed ID: 24615476
[TBL] [Abstract][Full Text] [Related]
38. Significant association of DIRC1 overexpression with tumor progression and poor prognosis in gastric cancer.
Li Z; Yang AJ; Wei FM; Zhao XH; Shao ZY
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8682-8689. PubMed ID: 30575946
[TBL] [Abstract][Full Text] [Related]
39. High basal Wnt signaling is further induced by PI3K/mTor inhibition but sensitive to cSRC inhibition in mammary carcinoma cell lines with HER2/3 overexpression.
Timmermans-Sprang EP; Gracanin A; Mol JA
BMC Cancer; 2015 Jul; 15():545. PubMed ID: 26205886
[TBL] [Abstract][Full Text] [Related]
40. Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.
Kanomata N; Kurebayashi J; Moriya T
Med Mol Morphol; 2019 Jun; 52(2):106-113. PubMed ID: 30317526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
